DBVT - Down 40% in 6 Months Is Aimmune Therapeutics a Buy?
Aimmune Therapeutics (NASDAQ: AIMT) has performed significantly worse than the broader market of late. The company's stock fell by more than 50% during the first quarter of the year, and even though it has rebounded somewhat, Aimmune's shares are still down by 43% year to date. If Aimmune can stage a strong comeback in the coming months, now may be an excellent time to purchase shares of this biotech stock for a discount.
The company's ability to turn things around will depend on what is arguably its main claim to fame: Earlier this year, Aimmune's drug Palforzia became the first treatment for peanut allergies to be approved by the U.S. Food and Drug Administration (FDA). Aimmune made quite a few headlines as a result of this achievement, but can this milestone help the company recover from its recent slump?
Image source: YCharts.